Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biohaven Ltd. Common Shares (NY:BHVN)

14.60 -0.43 (-2.89%)
Streaming Delayed Price Updated: 9:43 AM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biohaven Ltd. Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Mid-Afternoon Market Update: Nasdaq Jumps Over 200 Points; Crude Oil Down 3%
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Dow Reverses Morning Rally as Recession Fears Swirl
Stocks are shedding their premarket gains at midday, and are now looking to extend yesterday's major selloff. 
Via Talk Markets
Mid-Day Market Update: U.S. Stocks Turn Lower; Biohaven Pharmaceutical Shares Jump
U.S. stocks turned mostly lower midway through trading, with the Dow Jones dropping more than 100 points on Tuesday. 
Via Benzinga
Recap: Biohaven Pharma Hldgs Q1 Earnings
Biohaven Pharma Hldgs (NYSE:BHVN) reported its Q1 earnings results on Tuesday, May 10, 2022 at 06:50 AM. Here's what investors need to know about the announcement. 
Via Benzinga
77 Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Pfizer Buys Biohaven In A $12 Billion Deal That 'Couldn't Have Come At A Better Time'
One analyst says the deal "couldn't have come at a better time." Here's why. 
Via Investor's Business Daily
Pfizer Acquires This Migraine Drug Maker For $11B: What Investors Need To Know
Via Benzinga
BHVN Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Biohaven Pharmaceutical Holding Company Ltd. Is Fair to Shareholders
From Halper Sadeh LLP
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Pfizer to Acquire Biohaven Pharmaceuticals
From Pfizer Inc.
Via Business Wire
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
European Commission Granted Marketing Authorization For Pfizer and Biohaven's VYDURA® (Rimegepant) For Migraine
European Commission (EC) has granted marketing authorization for VYDURA® (rimegepant) for both the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine in adults who... 
Via Benzinga
Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine
From Pfizer Inc.
Via Business Wire
Axsome Therapeutics' Good Fortune Reverses As Its Migraine Drug Hits A Hurdle
Last week, Axsome stock soared on its depression drug. This week is a different story. 
Via Investor's Business Daily
AbbVie Stock Breaks Its Stride As Key Executive Departs For Flagship
Flagship Pioneering is swiping one of AbbVie's biggest names. 
Via Investor's Business Daily
Biohaven Pharma Holdings Stock Joins Elite Club Of Stocks With RS Ratings Over 90
On Wednesday, Biohaven Pharma Holdings stock had its Relative Strength (RS) Rating upgraded to 92 from 86 a day ago. 
Via Investor's Business Daily
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with... 
Via Benzinga
Biohaven Pharmaceutical's Return On Capital Employed Insights
Biohaven Pharmaceutical (NYSE:BHVN) brought in sales totaling $190.01 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 15.81%, resulting... 
Via Benzinga
Biohaven Stock Dives As 'Hand-Wringing' Clouds Two Potentially Promising Deals
Biohaven inked a pair of deals that one analyst find promising for its pipeline. 
Via Investor's Business Daily
Biohaven Further Deepens Its Neurology Pipeline With Bristol Myers, Knopp Biosciences Deals
Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) has entered into a global license agreement with Bristol Myers Squibb & Co (NYSE: BMY) to... 
Via Benzinga
The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse Split, Reata Awaits FDA Decision
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Lilly's Co-developed Diabetes Drug Jardiance Gets Label Expansion To... 
Via Benzinga
Biohaven Pharma: Q4 Earnings Insights
Biohaven Pharma Hldgs (NYSE:BHVN) reported its Q4 earnings results on Friday, February 25, 2022 at 07:30 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
Biohaven Pharmaceutical's Earnings Outlook
Biohaven Pharmaceutical (NYSE:BHVN) is set to give its latest quarterly earnings report on Friday, 2022-02-25. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
Biohaven/Pfizer Partnered Rimegepant Asia-Pacific Migraine Trial Meets Primary Endpoints
Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) and Pfizer Inc (NYSE: PFE) reported topline results from an Asia-Pacific, Phase 3 trial of... 
Via Benzinga
New Psychedelics ETF Launches On NYSE Arca
Elemental Advisors Inc. has launched its first ETF, composed of companies involved in research, development, production or use of psychedelics to address medical conditions. The PSYK ETF (NYSE: PSYK)... 
Via Benzinga
Earnings Scheduled For February 25, 2022
Companies Reporting Before The Bell • ACM Research (NASDAQ:ACMR) is estimated to report quarterly earnings at $0.64 per share on revenue of $89.53 million. •... 
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.